ArticleOphthalmology and therapy2021
Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.
Article in Ophthalmology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey.Ophthalmology and therapy · 2026Article
- Validation and Development of Claims-Based Algorithms for Identifying Thyroid Eye Disease Using the IRIS Registry-Komodo Linked Database.Journal of clinical medicine · 2026Article
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- Higher serum IgG4 levels correlate with better quality of life in mild Graves' orbitopathy: a preliminary report.Endocrine connections · 2026Article
- Development and external validation of a nomogram for identifying patients with thyroid eye disease who screen positive for depressive symptoms: a two-center study.Frontiers in endocrinology · 2026Observational
- Impact of graves'ophthalmopathy on quality of life, depression, and anxiety among turkish patients.Irish journal of medical science · 2025Article
- Quality and content evaluation of thyroid eye disease treatment information on TikTok and Bilibili.Scientific reports · 2025Article
- Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.Journal of the Endocrine Society · 2025Review
- Investigating factors influencing quality of life in thyroid eye disease: insight from machine learning approaches.European thyroid journal · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Percutaneous para-levator palpebrae superioris and subconjunctival injection of triamcinolone acetonide for upper eyelid retraction in thyroid-associated ophthalmopathy.Frontiers in medicine · 2025Article
- CT-based artificial intelligence prediction model for ocular motility score of thyroid eye disease.Endocrine · 2024Article
- Otolaryngologist surgical preferences for orbital decompression in thyroid eye disease: A North American survey.Laryngoscope investigative otolaryngology · 2024Article
- Psychological aspects of Graves' ophthalmopathy.Endocrine connections · 2024Review
- Article
- Impact of hyperthyroidism and its treatment on the outcome of mental health, occupational functioning, and quality of life: A naturalistic, prospective study.Indian journal of psychiatry · 2023Article
- Differentially expressed genes in orbital adipose/connective tissue of thyroid-associated orbitopathy.PeerJ · 2023Article
- How patients experience thyroid eye disease.Frontiers in endocrinology · 2023Article
- Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.European thyroid journal · 2022Article
- Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.Thyroid : official journal of the American Thyroid Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThyroid eye disease (TED) is an autoimmune disease that causes retro-orbital inflammation and subsequent proptosis, corneal exposure, strabismus, and variable vision changes. European studies have shown that TED can severely impact quality of life (QOL), but little is known about the QOL of patients with TED in the USA. Given that patient QOL influences TED severity classifications and subsequent treatment, understanding physician-perceived patient QOL is extremely important.
methodsThis retrospective chart review (conducted in 2018) examined QOL in US patients with moderate-to-severe TED, as reported by treating physicians who regularly manage patients with TED (≥ 5 patients in prior 12 months). The physicians graded patients' overall QOL (7-point Likert scale; 1 = "not at all impaired", 7 = "extremely impaired"), assessing mental health, vision changes, and ocular structural signs/symptoms. Patient demographics and clinical findings were examined to understand the impact of disease presentation on physician-perceived QOL.
resultsMedical record data of 714 US patients with moderate-to-severe TED were provided by 181 physicians (73 endocrinologists, 108 ophthalmologists). Patients had a mean age of 49.4 (standard deviation [SD] 13.6) years, and 102 cases (14%) were severe. Anxiety and/or depression was reported in 36% of patients (an increase from the 18.9% prevalence reported for the USA in 2017 by the US National Institute of Mental Health; P < 0.001). The mean physician-reported QOL impact score was 4.1 (SD 1.5). Furthermore, 62 and 89% of patients with moderate and severe TED, respectively, had a high physician-perceived QOL impact (≥ 4). The higher QOL impact group had significantly higher rates of pain symptoms, visual disturbances (including diplopia), and orbito-facial structural changes. Higher disease activity and severity were associated with lower physician-perceived QOL.
conclusionPatients' QOL, as evaluated by US physicians, is highly impacted by the activity and severity of TED. Additionally, mental health issues were more frequently reported by patients with TED than in the general US population. Ocular pain, strabismus, and diplopia appear to be main drivers of physician-perceived QOL impairment in this sample of US patients with TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.